RecruitingIgANC3GComplement-mediated Kidney Disease
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Eligible age
18+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Sponsor: ADARx Pharmaceuticals, Inc.
You may qualify if…
- ✓ Mean eGFR greater than or equal to 30 mL/min/1.73m2
- ✓ Clinical evidence of active kidney disease
- ✓ Treated with supportive care including an ACE inhibitor or ARB if applicable
- ✓ Willing to receive required vaccinations
- ✓ Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
You may not qualify if…
- ✕ Hereditary or acquired complement deficiency
- ✕ Kidney transplant or renal replacement therapy
- ✕ History of solid organ transplant
- ✕ Other kidney disease
- ✕ History of recurrent invasive infections
- ✕ Received complement inhibitor treatments
- ✕ Active systemic viral, bacterial, or fungal infection
- ✕ Abnormal liver function
Where it's recruiting
Source: ClinicalTrials.gov · NCT06989359 · last updated 2026-07-27